Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Hope"

604 News Found

Cipla launches needle-free inhalable insulin Afrezza in India
News | December 26, 2025

Cipla launches needle-free inhalable insulin Afrezza in India

Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge


Abbott’s Volt PFA System gets FDA nod
News | December 24, 2025

Abbott’s Volt PFA System gets FDA nod

AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life


Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
Biotech | December 24, 2025

Enveda launches Phase 1 trial for first-in-class Oral IBD therapy

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers


FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
Drug Approval | December 23, 2025

FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy

The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity


MARAbio launches first blood test to detect maternal autoantibody-linked autism
R&D | December 22, 2025

MARAbio launches first blood test to detect maternal autoantibody-linked autism

The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water


Fortis invests  Rs. 840 crore for 300+ beds in Bengaluru
Hospitals | December 20, 2025

Fortis invests Rs. 840 crore for 300+ beds in Bengaluru

Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore


Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
Clinical Trials | December 18, 2025

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint


FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer
Drug Approval | December 18, 2025

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis